Smoking cessation strategies in patients with peripheral arterial disease: An evidence-based approach

European Journal of Vascular and Endovascular Surgery

Volumn 26, Issue 4, 2003, Pages 341-347

  Hobbs, Simon D ^a   Bradbury, A W ^a  

^a UNIVERSITY HOSPITALS BIRMINGHAM NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

Bupropion; Nicotine replacement; Peripheral arterial disease; Smoking cessation; Therapy

Indexed keywords

AMFEBUTAMONE; ANTIDEPRESSANT AGENT; NICOTINE; PLACEBO;

ACUPRESSURE; ACUPUNCTURE; ADDICTION; APHTHOUS ULCER; ARTERY DISEASE; ATHEROSCLEROSIS; AVERSION THERAPY; AWARENESS; CLINICAL TRIAL; COCHRANE LIBRARY; COST EFFECTIVENESS ANALYSIS; COUGHING; DISEASE COURSE; DRUG ABSORPTION; DRUG CONTRAINDICATION; DRUG DELIVERY SYSTEM; DRUG FORMULATION; EPISTAXIS; EVIDENCE BASED MEDICINE; HEALTH CARE DELIVERY; HEALTH CARE QUALITY; HUMAN; HYPNOSIS; INDIGESTION; INSOMNIA; MEDLINE; META ANALYSIS; NICOTINE REPLACEMENT THERAPY; NOSE IRRITATION; PRIORITY JOURNAL; PSYCHOLOGICAL ASPECT; RASH; REVIEW; RISK FACTOR; SEIZURE; SMOKING CESSATION; THROAT DISEASE; TOBACCO DEPENDENCE; TREATMENT OUTCOME; TREATMENT PLANNING; XEROSTOMIA;

EID: 0142091655     PISSN: 10785884     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1078-5884(03)00356-3     Document Type: Article

References (43)

1. Burns P, Gough S, Bradbury AW. Management of peripheral arterial disease in primary care. Br Med J 2003; 326: 584-588.
2. Burns PJ, Lima E, Bradbury AW. What constitutes best medical therapy for peripheral arterial disease? Eur J Vasc Endovasc Surg 2002; 24: 6-12.
3. Kannel WB, Shurtleff D. The Framingham study. Cigarettes and the development of intermittent claudication. Geriatrics 1973; 28(2): 61-68.
4. Cole CW, Hill GB, Farzad E, Bouchard A, Moher D, Rody K et al. Cigarette smoking and peripheral arterial occlusive disease. Surgery 1993; 114: 753-757.
5. Burns PJ, Lima E, Bradbury AW. Second best medical therapy. Eur J Vasc Endovasc Surg 2002; 24: 400-404.
6. Tobacco Advisory Group, Royal College of Physicians, Nicotine Addiction in Britain. London: Royal College of Physicians, 2000.
7. Moxman J. Nicotine addiction. Br Med J 2000; 320: 391-392.
8. Prochaska JO, DiClemente CC, Norcross JC. In search of how people change: applications to addictive behaviours. Am Psychol 1992; 47: 1102-1114.
9. Silagy C, Stead LF. Physician advice for smoking cessation (Cochrane Review). The Cochrane Library, Oxford: Update Software, 2002. Issue 4.
10. Anderson JE, Jorenby DE, Scott WJ, Fiore MC. Treating tobacco use and dependence: an evidence-based clinical practice guideline for tobacco cessation. Chest 2002; 121(3): 932-941.
11. Karnath B. Smoking cessation. Am J Med 2002; 112: 399-405.
12. Cote M. Vascular nurse as a smoking cessation specialist. J Vasc Nurs 2000; 18: 47-53.
13. Idle JR. Titrating exposure to tobacco smoke using cotinine - a minefield of misunderstanding. J Clin Epidemiol 1990; 43: 313-317.
14. Jarvis MJ, Tubstall-Pedoe H, Feyerabend C, Vesey C, Saloojee Y. Comparison of tests used to distinguish smokers from non-smokers. Am J Public Health 1987; 77: 1435-1438.
15. Silagy C, Lancaster T, Stead L, Mant D, Fowler G. Nicotine replacement therapy for smoking cessation (Cochrane Review). The Cochrane Library, Oxford: Update Software, 2002. Issue 4.
16. Raw M, McNeill A, West R. Smoking cessation guidelines for health professionals. Thorax 1998; 53(Suppl. 5): S1-S19.
17. NICE, A rapid and systematic review of the clinical and cost effectiveness of bupropion SR and nicotine replacement therapy (NRT) for smoking cessation. Technology Appraisal Guidance No. 39, National Institute for Clinical Excellence, 2002. http://www.nice.org.uk [Accessed: 16-2-2003].
18. McRobbie H, Hajek P. Nicotine replacement therapy in patients with cardiovascular disease: guidelines for health professionals. Addiction 2001; 96: 1547-1551.
19. Joseph AM, Norman SM, Ferry LH, Prochazka AV, Westman EC, Steele BG et al. The safety of transdermal nicotine as an aid to smoking cessation in patients with cardiac disease. N Engl J Med 1996; 336: 1792-1798.
20. Working Group for the Study of Transdermal Nicotine in Patients with Coronary Artery Disease, Nicotine replacement therapy for patients with coronary artery disease. Arch Intern Med 1994; 154: 989-995.
21. Daughton DM, Heatley SA, Prendergast JJ, Causey D, Knowles M, Rolf CN et al. Effect of transdermal nicotine delivery as an adjunct to low-intervention smoking cessation therapy. A randomized, placebo-controlled, double-blind study. Arch Intern Med 1991; 151(4): 749-752.
22. NICE, Guidance on the use of nicotine replacement therapy (NRT) and bupropion for smoking cessation. Technology Appraisal Guidance No. 39, National Institute for Clinical Excellence, 2002. http://www.nice.org.uk [Accessed, 16-2-2002].
23. Holm KJ, Spencer CM. Bupropion: a review of its use in the management of smoking cessation. Drugs 2000; 59(4): 1007-1024.
24. Peters MJ, Morgan LC. The pharmacotherapy of smoking cessation. Med J Aust 2002; 176: 486-490.
25. Jorenby DE, Leischow SJ, Nides MA, Rennard SI, Johnston JA, Hughes AR et al. A controlled trial of sustained-release bupropion, a nicotine patch, or both for smoking cessation. N Engl J Med 1999; 340: 685-691.
26. Hajek P, West R. Treating nicotine dependence: the case for specialist smoker's clinics. Addiction 1998; 93(5): 637-640.
27. West R, McNeill A, Raw M. Smoking cessation guidelines for health professionals: an update. Thorax 2000; 55: 987-999.
28. White AR, Rampes H, Ernst E. Acupuncture for smoking cessation (Cochrane Review). The Cochrane Library, Oxford: Update Software, 2002. Issue 4.
29. Abbot NC, Stead LF, White AR, Barnes J. Hypnotherpay for smoking cessation (Cochrane Review). The Cochrane Library, Oxford: Update Software, 2002. Issue 4.
30. Hajek P, Stead LF. Aversive smoking for smoking cessation (Cochrane review). The Cochrane Library. Oxford: Update Software, 2002. Issue 4.
31. Hughes JR, Stead LE, Lancaster T. Antidepressants for smoking cessation (Cochrane review). The Cochrane Library. Oxford: Update Software, 2002. Issue 4.
32. Fowkes FGR, Housley E, Riemersma RA, Macintyre CCA, Cawood EHH, Prescott RJ et al. Smoking, lipids, glucose intolerance, and blood pressure as risk factors for peripheral atherosclerosis compared with ischaemic heart disease in the Edinburgh artery study. Am J Epidemiol 1992; 135: 331-340.
33. Hirsch AT, Treat-Jacobson D, Lando HA, Hatsukami DK. The role of tobacco cessation, antiplatelet and lipid-lowering therapies in the treatment of peripheral arterial disease. Vasc Med 1997; 2: 243-251.
34. Lassila R, Lepantalo M. Cigarette smoking and the outcome after lower limb arterial surgery. Acta Chirurgica Scand 1988; 154: 635-640.
35. Jonason T, Bergstrom R. Cessation of smoking in patients with intermittent claudication. Acta Med Scand 1987; 221: 253-260.
36. Gardner AW. The effect of cigarette smoking on exercise capacity in patients with intermittent claudication. Vasc Med 1996; 1: 181-186.
37. Stonebridge PA, Bradbury AW, Murie JA. Continued smoking and the results of vascular reconstruction. Br J Surg 1994; 81: 51-52.
38. Wiseman S, Powell J, Greenhalgh R, McCollum C, Kenchington G, Alexander C et al. The influence of smoking and plasma factors on prosthetic graft patency. Eur J Vasc Surg 1990; 4: 57-61.
39. Carty CS, Huribal M, Marsan BU, Ricotta JJ, Dryjski M. Nicotine and its metabolite cotinine are mitogenic for human vascular smooth muscle cells. J Vasc Surg 1997; 25: 682-688.
40. Faulkner KW, House AK, Castleden WM. The effect of cessation of smoking on the accumulative survival rates of patients with symptomatic peripheral vascular disease. Med J Aust 1983; 1: 217-219.
41. Samet JM. The health benefits of smoking cessation. Med Clin N Am 1992; 76: 399-414.
42. West RJ. Acute effects of stopping smoking. http://www.rjwest. co.uk [Accessed, 18-03-2003].
43. Russell MAH. Nicotine intake and its regulation by smokers. In: Martin WR, Loon GRV, Iwamoto ET, Davis L, eds. Tobacco Smoking and Nicotine: A Neurobiological Approach. New York: Plenum Publishing Corporation, 1987: 25-50.